Comparative Pharmacology
Head-to-head clinical analysis: CLOXAPEN versus DURACILLIN A S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXAPEN versus DURACILLIN A S.
CLOXAPEN vs DURACILLIN A.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Penicillin G procaine is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
600,000 units intramuscularly once daily; or 1.2 million units intramuscularly every 12 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
0.5-1 hour in adults with normal renal function; prolonged to 7-10 hours in end-stage renal disease
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Primarily renal (60-90% unchanged via tubular secretion and glomerular filtration); minor biliary/fecal elimination (<10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic